Gregory Vidal, MD, PhD

Articles

Unmet Needs and Clinical Pearls for Metastatic Endometrial Cancer

November 1st 2022

Before closing out their conversation on endometrial cancer, Kathleen Moore and David O’Malley summarize unmet needs in the field and share a few clinical pearls on managing patients with the disease.

Emerging Biomarkers and Drug Targets in mEC

October 25th 2022

Shared insight into novel biomarkers and potential drug targets being explored for treatment of metastatic endometrial cancer.

Looking Towards the Future: Moving Targeted Therapies for mEC Into the First-Line Setting

October 25th 2022

Experts discuss ongoing clinical trials focused on moving second-line and higher targeted therapies, including immunotherapy, into the frontline setting for mEC, and then comment on how these advances might impact treatment paradigms and patient outcomes.

Considerations for Second-Line and Higher Treatment of Recurrent mEC

October 18th 2022

Drs Moore and O’Malley discuss the second-line and higher targeted treatment options that they’d consider for patients with mEC who develop recurrent disease on or after chemotherapy.

First-Line Therapy for dMMR mEC: Patient Conversations and Treatment Goals

October 18th 2022

Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

October 17th 2022

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer

October 17th 2022

Ellen Ball, ANP-FNP, reviews how patients are monitored for treatment response and toxicities during first-line treatment.

Expert Commentary on the Patient’s Treatment Plan

October 11th 2022

Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.

A Review of mEC Incidence and Prognosis and Introduction of the Clinical Case

October 11th 2022

Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.

Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations

October 10th 2022

Key opinion leaders explain how early they introduce targeted therapy in mutated breast cancer.

Further Molecular Testing in Early-Stage Metastatic Breast Cancer

October 10th 2022

Gregory Vidal, MD, PhD, discusses the potential use of further molecular testing in early-stage first-line breast cancer.

Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer

September 26th 2022

Martin Dietrich, MD, PhD, explains the rationale for the chosen treatment approach in the presented clinical scenario of metastatic lung cancer.

Clinical Scenario: A 74-Year-Old Man with Lung Cancer

September 26th 2022

A panel of experts discusses the clinical scenario of a 74-year-old man with metastatic lung cancer and the best genetic testing approach.

Discussing Biomarker Testing with Patients

September 20th 2022

Ellen Ball, ANP-FNP, provides a look at the conversations she has with patients when discussing their options for genetic testing in breast cancer.

Use of Liquid Biopsies in Breast Cancer

September 20th 2022

Drs McKenzie and Vidal debate the use of liquid biopsies in breast cancer.

Challenges of Biomarker Testing in Breast Cancer

September 12th 2022

Dr Gregory Vidal describes the approaches for biomarker testing in breast cancer and the challenges clinicians face.

Biomarker Testing Interpretation in Breast and Lung Cancer

September 12th 2022

Andrew McKenzie, PhD, details how to interpret the results of biomarker testing in breast cancer and lung cancer.

Choosing a Molecular Testing Panel for Solid Tumors

September 6th 2022

Dr Andrew McKenzie explains how to choose the appropriate molecular testing for a patient.

Currently Targetable Mutations in Lung and Breast Cancer

September 6th 2022

Drs Dietrich and Vidal discuss the currently known targetable actionable mutations in breast cancer and lung cancer.

Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer

September 3rd 2022

Dr Martin Dietrich presents a second clinical scenario of a 44-year-old woman with metastatic, highly-aggressive breast cancer.